Compare Novo Nordisk A/S (NVO) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Starbucks Corp — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Starbucks Corp trades at $90.75 (market cap $106.26B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Starbucks Corp for 190 Days on average.
| NVO | SBUX | |
|---|---|---|
Market Cap | $165.31B | $106.26B |
Volume | 11,432,838 | 30,248,434 |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $108.55 |
52-Week Low | $35.29 | $78.46 |
Typical Hold Time | 116 Days | 190 Days |
Enterprise Value | $179.56B | $125.08B |
Dividend Yield | 4.71% | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Starbucks (SBUX) trades at $90.75, down 3.02% today, amid a bearish technical outlook and mixed fundamental performance. The company reported Q2 2026 EPS beat ($0.85 vs. $0.66 expected) but missed in Q4 2025, with revenue growth slowing to 2.8% year-over-year in 2025. Recent news highlights store closures (250 locations) and strategic portfolio reset, while analyst consensus remains positive with a $115.50 price target. Negative shareholder equity and elevated debt levels present financial concerns.
Outlook: Near-term pressure from restructuring and geopolitical risks, but long-term growth potential in high-performing locations and international markets. Risks include execution on store strategy, labor relations, and China exposure. Investment case hinges on successful turnaround and margin recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
